Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Structural Basis for E. coli Penicillin Binding Protein (PBP) 2 Inhibition, a Platform for Drug Design.

Levy N, Bruneau JM, Le Rouzic E, Bonnard D, Le Strat F, Caravano A, Chevreuil F, Barbion J, Chasset S, Ledoussal B, Moreau F, Ruff M.

J Med Chem. 2019 May 9;62(9):4742-4754. doi: 10.1021/acs.jmedchem.9b00338. Epub 2019 Apr 26.

PMID:
30995398
2.

Structure-function analyses unravel distinct effects of allosteric inhibitors of HIV-1 integrase on viral maturation and integration.

Bonnard D, Le Rouzic E, Eiler S, Amadori C, Orlov I, Bruneau JM, Brias J, Barbion J, Chevreuil F, Spehner D, Chasset S, Ledoussal B, Moreau F, Saïb A, Klaholz BP, Emiliani S, Ruff M, Zamborlini A, Benarous R.

J Biol Chem. 2018 Apr 20;293(16):6172-6186. doi: 10.1074/jbc.M117.816793. Epub 2018 Mar 5.

3.

The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity.

Amadori C, van der Velden YU, Bonnard D, Orlov I, van Bel N, Le Rouzic E, Miralles L, Brias J, Chevreuil F, Spehner D, Chasset S, Ledoussal B, Mayr L, Moreau F, García F, Gatell J, Zamborlini A, Emiliani S, Ruff M, Klaholz BP, Moog C, Berkhout B, Plana M, Benarous R.

Retrovirology. 2017 Nov 9;14(1):50. doi: 10.1186/s12977-017-0373-2.

4.

Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage.

Le Rouzic E, Bonnard D, Chasset S, Bruneau JM, Chevreuil F, Le Strat F, Nguyen J, Beauvoir R, Amadori C, Brias J, Vomscheid S, Eiler S, Lévy N, Delelis O, Deprez E, Saïb A, Zamborlini A, Emiliani S, Ruff M, Ledoussal B, Moreau F, Benarous R.

Retrovirology. 2013 Nov 21;10:144. doi: 10.1186/1742-4690-10-144.

5.

Vectorization efforts to increase Gram-negative intracellular drug concentration: a case study on HldE-K inhibitors.

Atamanyuk D, Faivre F, Oxoby M, Ledoussal B, Drocourt E, Moreau F, Gerusz V.

J Med Chem. 2013 Mar 14;56(5):1908-21. doi: 10.1021/jm400097h. Epub 2013 Feb 27.

PMID:
23445125
6.
7.

Unique biological properties and molecular mechanism of 5,6-bridged quinolones.

Macinga DR, Renick PJ, Makin KM, Ellis DH, Kreiner AA, Li M, Rupnik KJ, Kincaid EM, Wallace CD, Ledoussal B, Morris TW.

Antimicrob Agents Chemother. 2003 Aug;47(8):2526-37.

8.

Synthesis and biological testing of non-fluorinated analogues of levofloxacin.

Gray JL, Almstead JI, Gallagher CP, Hu XE, Kim NK, Taylor CJ, Twinem TL, Wallace CD, Ledoussal B.

Bioorg Med Chem Lett. 2003 Jul 21;13(14):2373-5.

PMID:
12824037
9.
10.

Non-fluorinated quinolones (NFQs): new antibacterials with unique properties against quinolone-resistant gram-positive pathogens.

Roychoudhury S, Ledoussal B.

Curr Drug Targets Infect Disord. 2002 Mar;2(1):51-65. Review.

PMID:
12462153
11.

Staphylococcus aureus mutants isolated via exposure to nonfluorinated quinolones: detection of known and unique mutations.

Roychoudhury S, Twinem TL, Makin KM, Nienaber MA, Li C, Morris TW, Ledoussal B, Catrenich CE.

Antimicrob Agents Chemother. 2001 Dec;45(12):3422-6.

12.

Activity of non-fluorinated quinolones (NFQs) against quinolone-resistant Escherichia coli and Streptococcus pneumoniae.

Roychoudhury S, Twinem TL, Makin KM, McIntosh EJ, Ledoussal B, Catrenich CE.

J Antimicrob Chemother. 2001 Jul;48(1):29-36.

PMID:
11418510
13.

Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.

Roychoudhury S, Catrenich CE, McIntosh EJ, McKeever HD, Makin KM, Koenigs PM, Ledoussal B.

Antimicrob Agents Chemother. 2001 Apr;45(4):1115-20.

14.

Fluoronaphthyridines and -quinolones as antibacterial agents. 5. Synthesis and antimicrobial activity of chiral 1-tert-butyl-6-fluoro-7-substituted-naphthyridones.

Di Cesare P, Bouzard D, Essiz M, Jacquet JP, Ledoussal B, Kiechel JR, Remuzon P, Kessler RE, Fung-Tomc J, Desiderio J.

J Med Chem. 1992 Oct 30;35(22):4205-13.

PMID:
1433222
15.

Fluoronaphthyridines as antibacterial agents. 4. Synthesis and structure-activity relationships of 5-substituted-6-fluoro-7-(cycloalkylamino)-1,4-dihydro-4-oxo-1,8- naphthyridine-3-carboxylic acids.

Bouzard D, Di Cesare P, Essiz M, Jacquet JP, Ledoussal B, Remuzon P, Kessler RE, Fung-Tomc J.

J Med Chem. 1992 Feb 7;35(3):518-25.

PMID:
1738144
16.

Potent non-6-fluoro-substituted quinolone antibacterials: synthesis and biological activity.

Ledoussal B, Bouzard D, Coroneos E.

J Med Chem. 1992 Jan;35(1):198-200. No abstract available.

PMID:
1732530

Supplemental Content

Loading ...
Support Center